PL2875026T3 - Pochodne imidazopirydyny stosowane w leczeniu cukrzycy - Google Patents

Pochodne imidazopirydyny stosowane w leczeniu cukrzycy

Info

Publication number
PL2875026T3
PL2875026T3 PL13744752T PL13744752T PL2875026T3 PL 2875026 T3 PL2875026 T3 PL 2875026T3 PL 13744752 T PL13744752 T PL 13744752T PL 13744752 T PL13744752 T PL 13744752T PL 2875026 T3 PL2875026 T3 PL 2875026T3
Authority
PL
Poland
Prior art keywords
diabetes
treatment
derivative used
imidazopyridine derivative
imidazopyridine
Prior art date
Application number
PL13744752T
Other languages
English (en)
Inventor
Franck F. Lepifre
Gersande R. Lena
Valérie Autier
Micheline R. Kergoat
Christine G. Charon
Sophie N. Raynal
Annick M. Audet
Original Assignee
Metabrain Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabrain Research filed Critical Metabrain Research
Publication of PL2875026T3 publication Critical patent/PL2875026T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13744752T 2012-07-20 2013-07-16 Pochodne imidazopirydyny stosowane w leczeniu cukrzycy PL2875026T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1257082A FR2993564B1 (fr) 2012-07-20 2012-07-20 Derives d'imidazopyridine utiles dans le traitement du diabete

Publications (1)

Publication Number Publication Date
PL2875026T3 true PL2875026T3 (pl) 2017-02-28

Family

ID=46785742

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13744752T PL2875026T3 (pl) 2012-07-20 2013-07-16 Pochodne imidazopirydyny stosowane w leczeniu cukrzycy

Country Status (13)

Country Link
US (1) US9381191B2 (pl)
EP (1) EP2875026B1 (pl)
JP (1) JP6154007B2 (pl)
KR (1) KR102132744B1 (pl)
AU (1) AU2013291866B2 (pl)
CA (1) CA2879054C (pl)
DK (1) DK2875026T3 (pl)
ES (1) ES2602056T3 (pl)
FR (1) FR2993564B1 (pl)
PL (1) PL2875026T3 (pl)
PT (1) PT2875026T (pl)
RU (1) RU2648242C2 (pl)
WO (1) WO2014013182A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005489A2 (pt) 2017-09-22 2020-09-24 Jubilant Epipad Llc, composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
EP3765453A1 (en) 2018-03-13 2021-01-20 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612086B2 (en) * 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
EP2072516A1 (en) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists
FR2925905B1 (fr) * 2008-01-02 2010-11-05 Sanofi Aventis DERIVES DE 2-BENZOYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2168965A1 (en) * 2008-09-25 2010-03-31 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators

Also Published As

Publication number Publication date
FR2993564B1 (fr) 2014-08-22
EP2875026A1 (fr) 2015-05-27
CN104662020A (zh) 2015-05-27
KR102132744B1 (ko) 2020-07-10
EP2875026B1 (fr) 2016-09-21
DK2875026T3 (en) 2017-01-09
RU2015101211A (ru) 2016-09-10
US20150182507A1 (en) 2015-07-02
FR2993564A1 (fr) 2014-01-24
PT2875026T (pt) 2016-12-13
AU2013291866B2 (en) 2017-08-10
WO2014013182A1 (fr) 2014-01-23
JP2015522602A (ja) 2015-08-06
US9381191B2 (en) 2016-07-05
JP6154007B2 (ja) 2017-06-28
CA2879054A1 (fr) 2014-01-23
CA2879054C (fr) 2021-02-09
AU2013291866A1 (en) 2015-02-26
KR20150032910A (ko) 2015-03-30
RU2648242C2 (ru) 2018-03-23
ES2602056T3 (es) 2017-02-17

Similar Documents

Publication Publication Date Title
IL275874A (en) Therapeutic use of adenovirus
IL263661A (en) Combination therapy for the treatment of glioblastoma
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
EP2939625A4 (en) THERAPEUTIC TREATMENT DEVICE
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
ZA201500229B (en) Combinations of modalities for the treatment of diabetes
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SI2812013T1 (sl) Formulacija za zdravljenje SRČ-ja
AU348530S (en) Wheelchair
GB201201927D0 (en) Wheelchair
GB201218084D0 (en) Novel compounds and methods for use in medicine
GB201207305D0 (en) Therapy
EP2837326A4 (en) MEDICAL APPARATUS
PL2875026T3 (pl) Pochodne imidazopirydyny stosowane w leczeniu cukrzycy
EP2807980A4 (en) MEDICAL TREATMENT DEVICE
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
GB201205189D0 (en) Novel medical use
ZA201502153B (en) Pyridinone compounds for use in photodynamic therapy
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
ZA201408065B (en) Compositions and methods for the treatment of diabetes
GB201215502D0 (en) Medical use
EP2804853A4 (en) THERAPEUTIC USES
GB201202094D0 (en) Medical apparatus
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
GB201211135D0 (en) Treatment